ArriVent BioPharma预计将在2026年初公布关于外显子20插入突变非小细胞肺癌(NSCLC)全球三期临床试验的关键数据。
ArriVent BioPharma预计将在2026年初公布关于外显子20插入突变非小细胞肺癌(NSCLC)全球三期临床试验的关键数据。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.